Characterization of mutations in ATP8B1 associated with hereditary cholestasis

Department of Metabolic and Endocrine Diseases, University Medical Center, Utrecht, The Netherlands.
Hepatology (Impact Factor: 11.19). 07/2004; 40(1):27-38. DOI: 10.1002/hep.20285
Source: PubMed

ABSTRACT Progressive familial intrahepatic cholestasis (PFIC) and benign recurrent intrahepatic cholestasis (BRIC) are clinically distinct hereditary disorders. PFIC patients suffer from chronic cholestasis and develop liver fibrosis. BRIC patients experience intermittent attacks of cholestasis that resolve spontaneously. Mutations in ATP8B1 (previously FIC1) may result in PFIC or BRIC. We report the genomic organization of ATP8B1 and mutation analyses of 180 families with PFIC or BRIC that identified 54 distinct disease mutations, including 10 mutations predicted to disrupt splicing, 6 nonsense mutations, 11 small insertion or deletion mutations predicted to induce frameshifts, 1 large genomic deletion, 2 small inframe deletions, and 24 missense mutations. Most mutations are rare, occurring in 1-3 families, or are limited to specific populations. Many patients are compound heterozygous for 2 mutations. Mutation type or location correlates overall with clinical severity: missense mutations are more common in BRIC (58% vs. 38% in PFIC), while nonsense, frameshifting, and large deletion mutations are more common in PFIC (41% vs. 16% in BRIC). Some mutations, however, lead to a wide range of phenotypes, from PFIC to BRIC or even no clinical disease. ATP8B1 mutations were detected in 30% and 41%, respectively, of the PFIC and BRIC patients screened.

Download full-text


Available from: Carlos Pabón Peña, Dec 03, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Neonatal cholestasis is one of the commonest presentations in the field of pediatric hepatology and gastroenterology and constitutes the major indication for liver transplantation below two years of age. Unfortunately, in spite of being common, fewer categories are amenable to curative or palliative therapy. Moreover, delayed referral to specialized centers is still a problem adding a more difficulty to neonatal cholestasis management. Hepatobiliary surgery is a major line of therapy in some etiologies of neonatal cholestasis. Biliary atresia, choledochal cyst, spontaneous perforation of the bile duct and inspissated bile syndrome are among the commonest known causes for hepatobiliary surgeons. However, there is less orientation about other causes, resulting in progression to cirrhosis and end stage liver disease without being diagnosed. One of these is the progressive familial intrahepatic cholestasis (PFIC) group of diseases. PFIC is an autosomal recessive liver disorder characterized by an intrahepatic cholestasis due to bile canalicular transport defects. It is subdivided into three types with slightly different clinical, biochemical and histological features. PFIC types 1, 2 and 3 are due to mutations in ATP8B1 (adenosine triphosphatase, type 8B, member 1), ABCB11 (adenosine triphosphate-binding cassette, subfamily B, member 11) and ABCB4 (adenosine triphosphate-binding cassette, subfamily B, member 4) genes, respectively. Each of these genes encodes a hepatocanalicular transporter which is essential for the proper secretion and formation of bile. PFIC1 and PFIC2 usually appear in the first months of life, whereas onset of PFIC3 may also occur later in infancy, in childhood or even during young adulthood. The shared main clinical manifestations in all types are cholestasis and pruritus. PFIC represents 10-15 % of causes of cholestasis in children and 10-15% of indications of liver transplantations in children. In this chapter, we want to highlight the etiology, pathophysiology, clinical presentation and the role of surgery in the management of this disease category, especially that medical therapy is of limited value in a magnitude of cases. Moreover, liver transplant is not without significant side effects. So, raising the orientation about this not uncommon condition will help in timely surgical intervention and improving patients' outcome.
    Hepatic Surgery, 1st edited by Abdeldayem H, 02/2013: chapter Progressive Familial Intrahepatic Cholestasis: pages 563-588; InTech., ISBN: 978-953-51-0965-5
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Benign recurrent intrahepatic cholestasis (BRIC) is a rare autosomal recessive inherited disorder characterized by intermittent episodes of cholestatic jaundice. For the patients, the disease is a physical and psychological challenge. There is no curable treatment, but symptomatic relief is described following treatment with rifampicin or plasmapheresis. Five patients suffering from BRIC followed up for 17 years by one consultant are described. Two patients were treated with rifampicin and plasmapheresis, two with rifampicin alone, and one with plasmapheresis. The treatments showed symptomatic relief, effect on biochemical parameters, and earlier clinical remission compared with no treatment or treatment with other substances like cholestyramine, antihistamines, and ursodeoxycholic acid. Both rifampicin and plasmapheresis represent important therapeutic options of acute cholestatic attacks in patients with BRIC. As a noninvasive treatment, rifampicin may be the first choice.
    Scandinavian Journal of Gastroenterology 01/2012; 47(4):482-8. DOI:10.3109/00365521.2011.650191 · 2.33 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Phospholipid flippases in the type IV P-type ATPase family (P4-ATPases) are essential components of the Golgi, plasma membrane and endosomal system that play critical roles in membrane biogenesis. These pumps flip phospholipid across the bilayer to create an asymmetric membrane structure with substrate phospholipids, such as phosphatidylserine and phosphatidylethanolamine, enriched within the cytosolic leaflet. The P4-ATPases also help form transport vesicles that bud from Golgi and endosomal membranes, thereby impacting the sorting and localization of many different proteins in the secretory and endocytic pathways. At the organismal level, P4-ATPase deficiencies are linked to liver disease, obesity, diabetes, hearing loss, neurological deficits, immune deficiency and reduced fertility. Here, we review the biochemical, cellular and physiological functions of P4-ATPases, with an emphasis on their roles in vesicle-mediated protein transport. This article is part of a Special Issue entitled Lipids and Vesicular Transport.
    Biochimica et Biophysica Acta 12/2011; 1821(8):1068-77. DOI:10.1016/j.bbalip.2011.12.007 · 4.66 Impact Factor